Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenigacestat combinations in advanced solid tumors
NCT02784795Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of crenigacestat in solid tumor (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities at Cycle 1. Started Nov 2016; status: terminated.
02
Drugs
crenigacestat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02784795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784795.